Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy

Arthritis Care and Research

Volumn 65, Issue 12, 2013, Pages 1969-1975

  Mamyrova, Gulnara ^a   Katz, James D ^a   Jones, Robert V ^a   Targoff, Ira N ^b   Lachenbruch, Peter A ^c   Jones, Olcay Y ^a   Miller, Frederick W ^c   Rider, Lisa G ^c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; MUSCLE ENZYME; PREDNISONE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONSTIPATION; DIAGNOSTIC ERROR; DYSPHAGIA; DYSPHONIA; ELECTROMYOGRAPHY; FALLING; FATIGUE; FEMALE; FEVER; HEART PALPITATION; HUMAN; INFLAMMATION; INTERSTITIAL LUNG DISEASE; JUVENILE POLYMYOSITIS; LIPODYSTROPHY; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYALGIA; MYOSITIS; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; POLYMYOSITIS; PREDICTOR VARIABLE; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFANT; MALE; MUSCULAR DYSTROPHIES; POLYMYOSITIS;

EID: 84886774808     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22088     Document Type: Article

References (31)

1. Rider LG, Lindsley C, Cassidy J,. Juvenile dermatomyositis. In:, Cassidy J, Petty R, Laxer R, Lindsley C, editors. Textbook of pediatric rheumatology. New York: Saunders Elsevier; 2011. p. 375-413.
2. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92: 25-41.
3. Feldman BM, Rider LG, Reed AM, Pachman LM,. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371: 2201-12.
4. Nirmalananthan N, Holton JL, Hanna MG,. Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheumatol 2004; 16: 684-91.
5. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 2009; 48: 134-9.
6. D'Arcy CE, Ryan MM, McLean CA,. Juvenile polymyositis or paediatric muscular dystrophy: a detailed re-analysis of 13 cases. Histopathology 2009; 55: 452-62.
7. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
8. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 3403-7.
9. Rosales XQ, Tsao CY,. Childhood onset of limb-girdle muscular dystrophy. Pediatr Neurol 2012; 46: 13-23.
10. Sewry CA,. Muscular dystrophies: an update on pathology and diagnosis. Acta Neuropathol 2010; 120: 343-58.
11. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360-74.
12. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379-87.
13. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD,. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996; 39: 1507-18.
14. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-9.
15. Malley JD, Malley KG, Pajevic S,. Statistical learning for biomedical data. Cambridge: Cambridge University Press; 2011.
16. Khadilkar SV, Patil SG, Amin SN,. Study of idiopathic inflammatory myopathies with special reference to borderland between idiopathic inflammatory myopathies and muscular dystrophies. Neurol India 2008; 56: 356-62.
17. Benveniste O, Romero NB,. Myositis or dystrophy? Traps and pitfalls. Presse Med 2011; 40: e249-55.
18. Degardin A, Morillon D, Lacour A, Cotten A, Vermersch P, Stojkovic T,. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol 2010; 39: 1219-27.
19. Hoffman EP, Rao D, Pachman LM,. Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. Rheum Dis Clin North Am 2002; 28: 743-57.
20. Ng KP, Smith CR, Isenberg DA,. Muscular dystrophy mimicking refractory idiopathic inflammatory myositis: a trio of cases [letter]. Rheumatology (Oxford) 2007; 46: 1618-9.
21. Miller FW,. Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In:, Koopman W, Moreland L, editors. A textbook of rheumatology. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1593-620.
22. Suzuki S, Satoh T, Sato S, Otomo M, Hirayama Y, Sato H, et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford) 2008; 47: 1539-42.
23. Hengstman GJ, van Brenk L, Vree Egberts WT, van der Kooi EL, Borm GF, Padberg GW, et al. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol 2005; 252: 534-7.
24. Qaun D,. Muscular dystrophies and neurologic diseases that present as myopathy. Rheum Dis Clin North Am 2011; 37: 233-44.
25. Baer AN,. Differential diagnosis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2006; 8: 178-87.
26. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000; 97: 9209-14.
27. Salaroli R, Baldin E, Papa V, Rinaldi R, Tarantino L, De Giorgi LB, et al. Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies. J Clin Pathol 2012; 65: 14-9.
28. Van der Pas J, Hengstman GJ, ter Laak HJ, Born GF, van Engelen BG,. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004; 75: 136-9.
29. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003; 142: 130-6.
30. Dalakas MC,. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies [published erratum appears in Nat Clin Pract Rheumatol 2006;2:398]. Nat Clin Pract Rheumatol 2006; 2: 219-27.
31. Rothman KJ,. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-6.